Publications

Found 1 results
Filters: Author is J.-A. Jiang  [Clear All Filters]
2013
C. - P. Liu, Jiang, J. - A., Wang, T., Liu, X. - M., Gao, L., Zhu, R. - R., Shen, Y., Wu, M., Xu, T., and Zhang, X. - G., CTLA-4 and CD86 genetic variants and haplotypes in patients with rheumatoid arthritis in southeastern China, vol. 12, pp. 1373-1382, 2013.
Abdallah AM, Renzoni EA, Anevlavis S, Lagan AL, et al. (2006). A polymorphism in the promoter region of the CD86 (B7.2) gene is associated with systemic sclerosis. Int. J. Immunogenet. 33: 155-161. http://dx.doi.org/10.1111/j.1744-313X.2006.00580.x PMid:16712644   Almasi S, Erfani N, Mojtahedi Z, Rajaee A, et al. (2006). Association of CTLA-4 gene promoter polymorphisms with systemic sclerosis in Iranian population. Genes Immun. 7: 401-406. http://dx.doi.org/10.1038/sj.gene.6364313 PMid:16775619   Arnett FC, Edworthy SM, Bloch DA, McShane DJ, et al. (1988). The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31: 315-324. http://dx.doi.org/10.1002/art.1780310302 PMid:3358796   Catalan D, Aravena O, Sabugo F, Wurmann P, et al. (2010). B cells from rheumatoid arthritis patients show important alterations in the expression of CD86 and FcgammaRIIb, which are modulated by anti-tumor necrosis factor therapy. Arthritis Res. Ther. 12: R68. http://dx.doi.org/10.1186/ar2985 PMid:20398308 PMCid:2888223   Chang JC, Liu CA, Chuang H, Ou CY, et al. (2004). Gender-limited association of cytotoxic T-lymphocyte antigen-4 (CTLA-4) polymorphism with cord blood IgE levels. Pediatr. Allergy Immunol. 15: 506-512. http://dx.doi.org/10.1111/j.1399-3038.2004.00161.x PMid:15610363   Fox D (2005). Etiology and Pathogenesis of Rheumatoid Arthritis. In: Arthritis and Allied Conditions (Koopman W, ed.). Lippincott Williams & Wilkins, Philadephia, 1089-1115.   Haimila K, Einarsdottir E, de Kauwe A, Koskinen LL, et al. (2009). The shared CTLA4-ICOS risk locus in celiac disease, IgA deficiency and common variable immunodeficiency. Genes Immun. 10: 151-161. http://dx.doi.org/10.1038/gene.2008.89 PMid:19020530   Howson JM, Walker NM, Smyth DJ and Todd JA (2009). Analysis of 19 genes for association with type I diabetes in the Type I Diabetes Genetics Consortium families. Genes Immun. 10 (Suppl 1): S74-S84. http://dx.doi.org/10.1038/gene.2009.96 PMid:19956106 PMCid:2810493   Jones AL, Holliday EG, Mowry BJ, McLean DE, et al. (2009). CTLA-4 single-nucleotide polymorphisms in a Caucasian population with schizophrenia. Brain Behav. Immun. 23: 347-350. http://dx.doi.org/10.1016/j.bbi.2008.09.008 PMid:18848621   Kouki T, Gardine CA, Yanagawa T and Degroot LJ (2002). Relation of three polymorphisms of the CTLA-4 gene in patients with Graves' disease. J. Endocrinol. Invest. 25: 208-213. PMid:11936461   Kusztal M, Kościelska-Kasprzak K, Drulis-Fajdasz D, Magott-Procelewska M, et al. (2010). The influence of CTLA-4 gene polymorphism on long-term kidney allograft function in Caucasian recipients. Transpl. Immunol. 23: 121-124. http://dx.doi.org/10.1016/j.trim.2010.05.002 PMid:20470888   Landi D, Moreno V, Guino E, Vodicka P, et al. (2011). Polymorphisms affecting micro-RNA regulation and associated with the risk of dietary-related cancers: a review from the literature and new evidence for a functional role of rs17281995 (CD86) and rs1051690 (INSR), previously associated with colorectal cancer. Mutat. Res. 717: 109-115. http://dx.doi.org/10.1016/j.mrfmmm.2010.10.002 PMid:20971123   Liang YL, Wu H, Li PQ, Xie XD, et al. (2011). Signal transducer and activator of transcription 4 gene polymorphisms associated with rheumatoid arthritis in Northwestern Chinese Han population. Life Sci. 89: 171-175. http://dx.doi.org/10.1016/j.lfs.2011.05.012 PMid:21683716   Ligers A, Teleshova N, Masterman T, Huang WX, et al. (2001). CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes Immun. 2: 145-152. http://dx.doi.org/10.1038/sj.gene.6363752 PMid:11426323   Liu MF, Kohsaka H, Sakurai H, Azuma M, et al. (1996). The presence of costimulatory molecules CD86 and CD28 in rheumatoid arthritis synovium. Arthritis Rheum. 39: 110-114. http://dx.doi.org/10.1002/art.1780390115 PMid:8546719   Liu Y, Liang WB, Gao LB, Pan XM, et al. (2010). CTLA4 and CD86 gene polymorphisms and susceptibility to chronic obstructive pulmonary disease. Hum. Immunol. 71: 1141-1146. http://dx.doi.org/10.1016/j.humimm.2010.08.007 PMid:20732370   Magistrelli G, Jeannin P, Herbault N, Benoit De CA, et al. (1999). A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. Eur. J. Immunol. 29: 3596-3602. http://dx.doi.org/10.1002/(SICI)1521-4141(199911)29:11<3596::AID-IMMU3596>3.0.CO;2-Y   Marin LA, Moya-Quiles MR, Miras M, Muro M, et al. (2005). Evaluation of CD86 gene polymorphism at +1057 position in liver transplant recipients. Transpl. Immunol. 15: 69-74. http://dx.doi.org/10.1016/j.trim.2005.04.003 PMid:16223675   Matsushita M, Tsuchiya N, Oka T, Yamane A, et al. (2000). New polymorphisms of human CD80 and CD86: lack of association with rheumatoid arthritis and systemic lupus erythematosus. Genes Immun. 1: 428-434. http://dx.doi.org/10.1038/sj.gene.6363704 PMid:11196673   Maurer M, Loserth S, Kolb-Maurer A, Ponath A, et al. (2002). A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1 +49) alters T-cell activation. Immunogenetics 54: 1-8. http://dx.doi.org/10.1007/s00251-002-0429-9 PMid:11976786   Orozco G, Rueda B and Martin J (2006). Genetic basis of rheumatoid arthritis. Biomed. Pharmacother. 60: 656-662. http://dx.doi.org/10.1016/j.biopha.2006.09.003 PMid:17055211   Pawlak E, Karabon L, Wlodarska-Polinska I, Jedynak A, et al. (2010). Influence of CTLA-4/CD28/ICOS gene polymorphisms on the susceptibility to cervical squamous cell carcinoma and stage of differentiation in the Polish population. Hum. Immunol. 71: 195-200. http://dx.doi.org/10.1016/j.humimm.2009.11.006 PMid:19913589   Plant D, Flynn E, Mbarek H, Dieude P, et al. (2010). Investigation of potential non-HLA rheumatoid arthritis susceptibility loci in a European cohort increases the evidence for nine markers. Ann. Rheum. Dis. 69: 1548-1553. http://dx.doi.org/10.1136/ard.2009.121020 PMid:20498205 PMCid:2938898   Rai E and Wakeland EK (2011). Genetic predisposition to autoimmunity - what have we learned? Semin. Immunol. 23: 67-83. http://dx.doi.org/10.1016/j.smim.2011.01.015 PMid:21288738   Scalapino KJ and Daikh DI (2008). CTLA-4: a key regulatory point in the control of autoimmune disease. Immunol. Rev. 223: 143-155. http://dx.doi.org/10.1111/j.1600-065X.2008.00639.x PMid:18613834   Sharpe AH and Freeman GJ (2002). The B7-CD28 superfamily. Nat. Rev. Immunol. 2: 116-126. http://dx.doi.org/10.1038/nri727 PMid:11910893   Sole X, Guino E, Valls J, Iniesta R, et al. (2006). SNPStats: a web tool for the analysis of association studies. Bioinformatics 22: 1928-1929. http://dx.doi.org/10.1093/bioinformatics/btl268 PMid:16720584   Su TH, Chang TY, Lee YJ, Chen CK, et al. (2007). CTLA-4 gene and susceptibility to human papillomavirus-16- associated cervical squamous cell carcinoma in Taiwanese women. Carcinogenesis 28: 1237-1240. http://dx.doi.org/10.1093/carcin/bgm043 PMid:17341658   Tivol EA, Borriello F, Schweitzer AN, Lynch WP, et al. (1995). Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3: 541-547. http://dx.doi.org/10.1016/1074-7613(95)90125-6   Wang XB, Zhao X, Giscombe R and Lefvert AK (2002). A CTLA-4 gene polymorphism at position -318 in the promoter region affects the expression of protein. Genes Immun. 3: 233-234. http://dx.doi.org/10.1038/sj.gene.6363869 PMid:12058260   Yadav D and Sarvetnick N (2007). B7-2 regulates survival, phenotype, and function of APCs. J. Immunol. 178: 6236- 6241. PMid:17475851   Zaletel K, Krhin B, Gaberscek S and Hojker S (2006). Thyroid autoantibody production is influenced by exon 1 and promoter CTLA-4 polymorphisms in patients with Hashimoto's thyroiditis. Int. J. Immunogenet. 33: 87-91. http://dx.doi.org/10.1111/j.1744-313X.2006.00574.x PMid:16611252